Navigation Links
Arena Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/9/2011

of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted when anticipated or the information provided in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena'
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
5. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
6. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
9. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
10. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
11. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... the stock of United Kingdom -based ... microbiological culture media and diagnostic systems. ... into a leading provider of microbial testing and diagnostic ... testing markets. The company currently sells into more than ...
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
(Date:8/27/2015)... ... 2015 , ... Proove Biosciences, a commercial and research ... genetics and hypertension at the International Academy of Cardiology Annual Scientific ... The event, which boasts an extensive overview of the latest research developments in ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes Research ... University of Miami Miller School of Medicine, announced ... trial to test for the first time a ... completed.  This FDA approved Phase I/II study builds ... and is an important first step toward the ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... , , , , , , , ... , 1636138, 1 kit, ... Package Inserts/Product , Instructions , , English , ... version - 39 K , , US Material Safety , ...
... , , , , Here are some troubleshooting hints that we have gathered , if your ... , , , ... , , , , ... template in the reaction is not optimal , , , ...
... , , Here are some troubleshooting hints that we have gathered , ... , , , , ... href="#Option1">Primer annealing temperature is too high , ... , , <a , ...
Cached Biology Technology:Trouble-shooting: No product 2Trouble-shooting: No product 3Trouble-shooting: No product 4Trouble-shooting: No product 5Trouble-shooting: Low yield 2Trouble-shooting: Low yield 3Trouble-shooting: Low yield 4Trouble-shooting: Low yield 5Trouble-shooting: Low yield 6Trouble-shooting: Low yield 7
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
(Date:8/12/2015)...  New research unveiled at Black Hat 2015 ... steal users, fingerprints. Information released today by HYPR ... on mobile devices, making the security of this ... mobile devices, HYPR Corp. recently released a biometric ... with strong cryptographic security. More information on this ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... ongoing research on biotic invasions around the world constantly ... in the United States shows how using improved data ... species changes the understanding of patterns of species naturalization, ... published in the open access journal NeoBiota ...
... discovered specific molecular and signaling events by which vitamin ... low levels of Vitamin D, comparable to levels found ... cascade, while levels considered adequate did inhibit inflammatory signaling. ... issue of The Journal of Immunology . , ...
... the potential severity of an outbreak of airborne H5N1 influenza ... instead on how we can safely continue H5N1 research and ... be published in mBio , the online open-access journal ... H5N1 influenza has been at the center of heated ...
Cached Biology News:Human population the primary factor in exotic plant invasions in the United States 2Researchers discover how vitamin D inhibits inflammation 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 2Opinion: H5N1 flu is just as dangerous as feared, now requires action 3
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: